Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma.

Ghatalia P, Gordetsky J, Kuo F, Dulaimi E, Cai KQ, Devarajan K, Bae S, Naik G, Chan TA, Uzzo R, Hakimi AA, Sonpavde G, Plimack E.

J Immunother Cancer. 2019 May 28;7(1):139. doi: 10.1186/s40425-019-0621-1.

2.

Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.

Barta SK, Zain J, MacFarlane AW 4th, Smith SM, Ruan J, Fung HC, Tan CR, Yang Y, Alpaugh RK, Dulaimi E, Ross EA, Campbell KS, Khan N, Siddharta R, Fowler NH, Fisher RI, Oki Y.

Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):356-364.e3. doi: 10.1016/j.clml.2019.03.022. Epub 2019 Apr 3.

PMID:
31029646
3.

Case report: reinitiating pembrolizumab treatment after small bowel perforation.

Beck TN, Kudinov AE, Dulaimi E, Boumber Y.

BMC Cancer. 2019 Apr 24;19(1):379. doi: 10.1186/s12885-019-5577-5.

4.

NEAT1-TFE3 and KAT6A-TFE3 renal cell carcinomas, new members of MiT family translocation renal cell carcinoma.

Pei J, Cooper H, Flieder DB, Talarchek JN, Al-Saleem T, Uzzo RG, Dulaimi E, Patchefsky AS, Testa JR, Wei S.

Mod Pathol. 2019 May;32(5):710-716. doi: 10.1038/s41379-018-0191-7. Epub 2019 Jan 8.

5.

Application of Chromosome Microarray Analysis for the Differential Diagnosis of Low-grade Renal Cell Carcinoma With Clear Cell and Papillary Features.

Pei J, Al-Saleem T, Uzzo RG, Dulaimi E, Testa JR, Wei S.

Appl Immunohistochem Mol Morphol. 2018 Nov 28. doi: 10.1097/PAI.0000000000000704. [Epub ahead of print]

PMID:
30499818
6.

Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial.

Anari F, O'Neill J, Choi W, Chen DYT, Haseebuddin M, Kutikov A, Dulaimi E, Alpaugh RK, Devarajan K, Greenberg RE, Bilusic M, Wong YN, Viterbo R, Hoffman-Censits JH, Lallas CD, Trabulsi EJ, Smaldone M, Geynisman DM, Zibelman M, Lin J, Kelly WK, Uzzo R, McConkey D, Plimack ER.

Eur Urol Oncol. 2018 May;1(1):54-60. doi: 10.1016/j.euo.2018.02.007. Epub 2018 Jun 6.

7.

Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer.

Liao L, Liu ZZ, Langbein L, Cai W, Cho EA, Na J, Niu X, Jiang W, Zhong Z, Cai WL, Jagannathan G, Dulaimi E, Testa JR, Uzzo RG, Wang Y, Stark GR, Sun J, Peiper S, Xu Y, Yan Q, Yang H.

Elife. 2018 Oct 25;7. pii: e37925. doi: 10.7554/eLife.37925.

8.

Miliary Adenocarcinoma of the Lung Responds to Gefitinib and Afatinib.

Beck TN, Kharin LV, Kit OI, Dulaimi E, Boumber Y.

J Thorac Oncol. 2018 Jun;13(6):e95-e97. doi: 10.1016/j.jtho.2018.01.018. No abstract available.

9.

The correlation between gain of chromosome 8q and survival in patients with clear and papillary renal cell carcinoma.

Mehrazin R, Dulaimi E, Uzzo RG, Devarjan K, Pei J, Smaldone MC, Kutikov A, Testa JR, Al-Saleem T.

Ther Adv Urol. 2017 Oct 31;10(1):3-10. doi: 10.1177/1756287217732660. eCollection 2018 Jan.

10.

Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer.

Liu D, Abbosh P, Keliher D, Reardon B, Miao D, Mouw K, Weiner-Taylor A, Wankowicz S, Han G, Teo MY, Cipolla C, Kim J, Iyer G, Al-Ahmadie H, Dulaimi E, Chen DYT, Alpaugh RK, Hoffman-Censits J, Garraway LA, Getz G, Carter SL, Bellmunt J, Plimack ER, Rosenberg JE, Van Allen EM.

Nat Commun. 2017 Dec 19;8(1):2193. doi: 10.1038/s41467-017-02320-7.

11.

Intratumoral heterogeneity analysis reveals hidden associations between protein expression losses and patient survival in clear cell renal cell carcinoma.

Jiang W, Dulaimi E, Devarajan K, Parsons T, Wang Q, O'Neill R, Solomides C, Peiper SC, Testa JR, Uzzo R, Yang H.

Oncotarget. 2017 Jun 6;8(23):37423-37434. doi: 10.18632/oncotarget.16965.

12.

Matrix-regulated integrin αvβ5 maintains α5β1-dependent desmoplastic traits prognostic of neoplastic recurrence.

Franco-Barraza J, Francescone R, Luong T, Shah N, Madhani R, Cukierman G, Dulaimi E, Devarajan K, Egleston BL, Nicolas E, Katherine Alpaugh R, Malik R, Uzzo RG, Hoffman JP, Golemis EA, Cukierman E.

Elife. 2017 Jan 31;6. pii: e20600. doi: 10.7554/eLife.20600.

13.

Low Level of Blood CD4+ T Cells Is an Independent Predictor of Inferior Progression-free Survival in Diffuse Large B-cell Lymphoma.

Judd J, Dulaimi E, Li T, Millenson MM, Borghaei H, Smith MR, Al-Saleem T.

Clin Lymphoma Myeloma Leuk. 2017 Feb;17(2):83-88. doi: 10.1016/j.clml.2016.11.005. Epub 2016 Nov 30.

PMID:
28027895
14.

Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma.

Jiang W, Dulaimi E, Devarajan K, Parsons T, Wang Q, Liao L, Cho EA, O'Neill R, Solomides C, Peiper SC, Testa JR, Uzzo R, Yang H.

PLoS One. 2016 Oct 20;11(10):e0164554. doi: 10.1371/journal.pone.0164554. eCollection 2016.

15.

Genomic imbalances in peripheral blood confirm the diagnosis of myelodysplastic syndrome in a patient presenting with non-immune hemolytic anemia.

Zahid MF, Khan N, Pei J, Testa JR, Dulaimi E.

Leuk Res Rep. 2016 May 13;5:23-6. doi: 10.1016/j.lrr.2016.05.001. eCollection 2016.

16.

Genomic Copy Number Alterations in Renal Cell Carcinoma with Sarcomatoid Features.

Ito T, Pei J, Dulaimi E, Menges C, Abbosh PH, Smaldone MC, Chen DY, Greenberg RE, Kutikov A, Viterbo R, Uzzo RG, Testa JR.

J Urol. 2016 Apr;195(4 Pt 1):852-8. doi: 10.1016/j.juro.2015.10.180. Epub 2015 Nov 18.

17.

Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.

Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, Viterbo R, Greenberg RE, Chen DY, Lallas CD, Trabulsi EJ, Yelensky R, McConkey DJ, Miller VA, Golemis EA, Ross EA.

Eur Urol. 2015 Dec;68(6):959-67. doi: 10.1016/j.eururo.2015.07.009. Epub 2015 Aug 1.

18.

Pak2 restrains endomitosis during megakaryopoiesis and alters cytoskeleton organization.

Kosoff RE, Aslan JE, Kostyak JC, Dulaimi E, Chow HY, Prudnikova TY, Radu M, Kunapuli SP, McCarty OJ, Chernoff J.

Blood. 2015 May 7;125(19):2995-3005. doi: 10.1182/blood-2014-10-604504. Epub 2015 Mar 30.

19.

Lymphopenia is an independent predictor of inferior outcome in papillary renal cell carcinoma.

Mehrazin R, Uzzo RG, Kutikov A, Ruth K, Tomaszewski JJ, Dulaimi E, Ginzburg S, Abbosh PH, Ito T, Corcoran AT, Chen DY, Smaldone MC, Al-Saleem T.

Urol Oncol. 2015 Sep;33(9):388.e19-25. doi: 10.1016/j.urolonc.2014.06.004. Epub 2014 Jul 11.

20.

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.

Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE, Chen DY, Lallas CD, Wong YN, Lin J, Kutikov A, Dotan E, Brennan TA, Palma N, Dulaimi E, Mehrazin R, Boorjian SA, Kelly WK, Uzzo RG, Hudes GR.

J Clin Oncol. 2014 Jun 20;32(18):1895-901. doi: 10.1200/JCO.2013.53.2465. Epub 2014 May 12.

21.

PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection.

MacFarlane AW 4th, Jillab M, Plimack ER, Hudes GR, Uzzo RG, Litwin S, Dulaimi E, Al-Saleem T, Campbell KS.

Cancer Immunol Res. 2014 Apr;2(4):320-31. doi: 10.1158/2326-6066.CIR-13-0133. Epub 2013 Nov 25.

22.

Copy neutral loss of heterozygosity in 20q in chronic lymphocytic leukemia/small lymphocytic lymphoma.

Pei J, Robu V, Feder M, Cheung M, Neumann-Domer E, Talarchek J, Dulaimi E, Millenson MM, Testa JR.

Cancer Genet. 2014 Mar;207(3):98-102. doi: 10.1016/j.cancergen.2014.02.005. Epub 2014 Feb 15.

23.

A global profile of gene promoter methylation in treatment-naïve urothelial cancer.

Ibragimova I, Dulaimi E, Slifker MJ, Chen DY, Uzzo RG, Cairns P.

Epigenetics. 2014 May;9(5):760-73. doi: 10.4161/epi.28078. Epub 2014 Feb 12.

24.

Genome-wide promoter methylome of small renal masses.

Ibragimova I, Slifker MJ, Maradeo ME, Banumathy G, Dulaimi E, Uzzo RG, Cairns P.

PLoS One. 2013 Oct 24;8(10):e77309. doi: 10.1371/journal.pone.0077309. eCollection 2013.

25.

Coexisting hybrid malignancy in a solitary sporadic solid benign renal mass: implications for treating patients following renal biopsy.

Ginzburg S, Uzzo R, Al-Saleem T, Dulaimi E, Walton J, Corcoran A, Plimack E, Mehrazin R, Tomaszewski J, Viterbo R, Chen DY, Greenberg R, Smaldone M, Kutikov A.

J Urol. 2014 Feb;191(2):296-300. doi: 10.1016/j.juro.2013.07.059. Epub 2013 Jul 27.

26.

Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.

Ibragimova I, Maradeo ME, Dulaimi E, Cairns P.

Epigenetics. 2013 May;8(5):486-93. doi: 10.4161/epi.24552. Epub 2013 May 1.

27.

Porcine intact and wounded skin responses to atmospheric nonthermal plasma.

Wu AS, Kalghatgi S, Dobrynin D, Sensenig R, Cerchar E, Podolsky E, Dulaimi E, Paff M, Wasko K, Arjunan KP, Garcia K, Fridman G, Balasubramanian M, Ownbey R, Barbee KA, Fridman A, Friedman G, Joshi SG, Brooks AD.

J Surg Res. 2013 Jan;179(1):e1-e12. doi: 10.1016/j.jss.2012.02.039. Epub 2012 Mar 10.

PMID:
22480830
28.

Global reactivation of epigenetically silenced genes in prostate cancer.

Ibragimova I, Ibáñez de Cáceres I, Hoffman AM, Potapova A, Dulaimi E, Al-Saleem T, Hudes GR, Ochs MF, Cairns P.

Cancer Prev Res (Phila). 2010 Sep;3(9):1084-92. doi: 10.1158/1940-6207.CAPR-10-0039. Epub 2010 Aug 10.

29.

Identification of novel target genes by an epigenetic reactivation screen of renal cancer.

Ibanez de Caceres I, Dulaimi E, Hoffman AM, Al-Saleem T, Uzzo RG, Cairns P.

Cancer Res. 2006 May 15;66(10):5021-8.

30.

Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.

Dulaimi E, Hillinck J, Ibanez de Caceres I, Al-Saleem T, Cairns P.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6189-93.

31.

Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients.

Ibanez de Caceres I, Battagli C, Esteller M, Herman JG, Dulaimi E, Edelson MI, Bergman C, Ehya H, Eisenberg BL, Cairns P.

Cancer Res. 2004 Sep 15;64(18):6476-81.

32.

Promoter hypermethylation profile of kidney cancer.

Dulaimi E, Ibanez de Caceres I, Uzzo RG, Al-Saleem T, Greenberg RE, Polascik TJ, Babb JS, Grizzle WE, Cairns P.

Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3972-9.

33.

The genetics of renal oncocytosis: a possible model for neoplastic progression.

Al-Saleem T, Cairns P, Dulaimi EA, Feder M, Testa JR, Uzzo RG.

Cancer Genet Cytogenet. 2004 Jul 1;152(1):23-8.

PMID:
15193438
34.

Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel.

Dulaimi E, Uzzo RG, Greenberg RE, Al-Saleem T, Cairns P.

Clin Cancer Res. 2004 Mar 15;10(6):1887-93.

35.

Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation.

Krassenstein R, Sauter E, Dulaimi E, Battagli C, Ehya H, Klein-Szanto A, Cairns P.

Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):28-32.

36.

Telomerase is frequently activated in tumors with microsatellite instability.

Ibanez de Caceres I, Frolova N, Varkonyi RJ, Dulaimi E, Meropol NJ, Broccoli D, Cairns P.

Cancer Biol Ther. 2004 Mar;3(3):289-92. Epub 2004 Mar 10.

PMID:
14726659
37.

Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients.

Battagli C, Uzzo RG, Dulaimi E, Ibanez de Caceres I, Krassenstein R, Al-Saleem T, Greenberg RE, Cairns P.

Cancer Res. 2003 Dec 15;63(24):8695-9.

Supplemental Content

Loading ...
Support Center